Carl Zeiss Meditec AG
Carl Zeiss Meditec AG Fundamental Analysis
Carl Zeiss Meditec AG (AFX.DE) shows weak financial fundamentals with a PE ratio of 15.96, profit margin of 6.34%, and ROE of 6.77%. The company generates $2.2B in annual revenue with moderate year-over-year growth of 7.82%.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 48.9/100 based on profitability, valuation, growth, and balance sheet metrics. The D grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze AFX.DE's fundamental strength across five key dimensions:
Efficiency Score
WeakAFX.DE struggles to generate sufficient returns from assets.
Valuation Score
ExcellentAFX.DE trades at attractive valuation levels.
Growth Score
ModerateAFX.DE shows steady but slowing expansion.
Financial Health Score
ExcellentAFX.DE maintains a strong and stable balance sheet.
Profitability Score
WeakAFX.DE struggles to sustain strong margins.
Key Financial Metrics
Is AFX.DE Expensive or Cheap?
P/E Ratio
AFX.DE trades at 15.96 times earnings. This indicates a fair valuation.
PEG Ratio
When adjusting for growth, AFX.DE's PEG of -4.60 indicates potential undervaluation.
Price to Book
The market values Carl Zeiss Meditec AG at 1.06 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at 4.65 times EBITDA. This is generally considered low.
How Well Does AFX.DE Make Money?
Net Profit Margin
For every $100 in sales, Carl Zeiss Meditec AG keeps $6.34 as profit after all expenses.
Operating Margin
Core operations generate 13.24 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $6.77 in profit for every $100 of shareholder equity.
ROA
Carl Zeiss Meditec AG generates $4.08 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Carl Zeiss Meditec AG generates limited operating cash flow of $183.56M, signaling weaker underlying cash strength.
Free Cash Flow
Carl Zeiss Meditec AG produces free cash flow of $144.16M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $1.65 in free cash annually.
FCF Yield
AFX.DE converts 6.40% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
15.96
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
-4.60
vs 25 benchmark
P/B Ratio
Price to book value ratio
1.06
vs 25 benchmark
P/S Ratio
Price to sales ratio
1.01
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
0.29
vs 25 benchmark
Current Ratio
Current assets to current liabilities
2.35
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.07
vs 25 benchmark
ROA
Return on assets percentage
0.04
vs 25 benchmark
ROCE
Return on capital employed
0.10
vs 25 benchmark
How AFX.DE Stacks Against Its Sector Peers
| Metric | AFX.DE Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 15.96 | 28.66 | Better (Cheaper) |
| ROE | 6.77% | 671.00% | Weak |
| Net Margin | 6.34% | -44168.00% (disorted) | Weak |
| Debt/Equity | 0.29 | 0.33 | Neutral |
| Current Ratio | 2.35 | 4.49 | Strong Liquidity |
| ROA | 4.08% | -17052.00% (disorted) | Weak |
AFX.DE outperforms its industry in 2 out of 6 key metrics, but lagging in ROE.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Carl Zeiss Meditec AG's 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
70.44%
Industry Style: Defensive, Growth, Innovation
High GrowthEPS CAGR
17.89%
Industry Style: Defensive, Growth, Innovation
High GrowthFCF CAGR
20.11%
Industry Style: Defensive, Growth, Innovation
High Growth